What is HC Wainwright’s Estimate for NTLA Q1 Earnings?

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a research note issued on Wednesday, March 5th. HC Wainwright analyst M. Kapoor expects that the company will post earnings of ($1.40) per share for the quarter. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share. HC Wainwright also issued estimates for Intellia Therapeutics’ Q2 2025 earnings at ($1.39) EPS, Q4 2025 earnings at ($1.43) EPS and Q4 2026 earnings at ($1.17) EPS.

A number of other brokerages also recently issued reports on NTLA. Wedbush reaffirmed a “neutral” rating and set a $10.00 price target (down from $14.00) on shares of Intellia Therapeutics in a report on Friday, January 10th. Morgan Stanley cut Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and cut their target price for the stock from $56.00 to $11.00 in a research report on Monday, January 27th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a research report on Monday. Citigroup lifted their target price on Intellia Therapeutics from $12.00 to $14.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $90.00 target price on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Intellia Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $37.56.

Intellia Therapeutics Price Performance

Shares of NASDAQ NTLA opened at $9.36 on Thursday. The company has a market capitalization of $968.92 million, a price-to-earnings ratio of -1.72 and a beta of 1.97. The business has a 50-day moving average of $10.69 and a two-hundred day moving average of $15.32. Intellia Therapeutics has a 1 year low of $8.30 and a 1 year high of $32.00.

Insider Activity at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 29,000 shares of company stock valued at $352,551. 3.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Regeneron Pharmaceuticals Inc. acquired a new stake in shares of Intellia Therapeutics during the 4th quarter worth $43,177,000. Voloridge Investment Management LLC increased its holdings in Intellia Therapeutics by 226.8% in the 4th quarter. Voloridge Investment Management LLC now owns 1,526,994 shares of the company’s stock valued at $17,805,000 after purchasing an additional 1,059,751 shares in the last quarter. Contrarius Group Holdings Ltd acquired a new stake in Intellia Therapeutics in the 4th quarter valued at $11,798,000. Two Sigma Advisers LP increased its holdings in Intellia Therapeutics by 94.5% in the 4th quarter. Two Sigma Advisers LP now owns 1,998,317 shares of the company’s stock valued at $23,300,000 after purchasing an additional 970,700 shares in the last quarter. Finally, Two Sigma Investments LP increased its holdings in Intellia Therapeutics by 88.1% in the 4th quarter. Two Sigma Investments LP now owns 1,843,743 shares of the company’s stock valued at $21,498,000 after purchasing an additional 863,363 shares in the last quarter. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.